ATE439357T1 - Indolylderivate als liver-x-rezeptormodulatoren - Google Patents
Indolylderivate als liver-x-rezeptormodulatorenInfo
- Publication number
- ATE439357T1 ATE439357T1 AT05751959T AT05751959T ATE439357T1 AT E439357 T1 ATE439357 T1 AT E439357T1 AT 05751959 T AT05751959 T AT 05751959T AT 05751959 T AT05751959 T AT 05751959T AT E439357 T1 ATE439357 T1 AT E439357T1
- Authority
- AT
- Austria
- Prior art keywords
- liver
- receptor modulators
- indolyl derivatives
- indolyl
- derivatives
- Prior art date
Links
- -1 INDOLYL Chemical class 0.000 title 1
- 102000004311 liver X receptors Human genes 0.000 title 1
- 108090000865 liver X receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04101889 | 2004-05-03 | ||
| PCT/EP2005/004454 WO2005105791A1 (en) | 2004-05-03 | 2005-04-26 | Indolyl derivatives as liver-x-receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE439357T1 true ATE439357T1 (de) | 2009-08-15 |
Family
ID=34970495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05751959T ATE439357T1 (de) | 2004-05-03 | 2005-04-26 | Indolylderivate als liver-x-rezeptormodulatoren |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7173048B2 (de) |
| EP (1) | EP1756096B1 (de) |
| JP (1) | JP4682192B2 (de) |
| KR (1) | KR100893449B1 (de) |
| CN (1) | CN1950365A (de) |
| AR (1) | AR049497A1 (de) |
| AT (1) | ATE439357T1 (de) |
| AU (1) | AU2005238176B2 (de) |
| BR (1) | BRPI0510599A (de) |
| CA (1) | CA2564563C (de) |
| DE (1) | DE602005015962D1 (de) |
| DK (1) | DK1756096T3 (de) |
| ES (1) | ES2329489T3 (de) |
| HR (1) | HRP20090533T1 (de) |
| IL (1) | IL178767A0 (de) |
| MX (1) | MXPA06012683A (de) |
| MY (1) | MY139571A (de) |
| NO (1) | NO20065503L (de) |
| NZ (1) | NZ550447A (de) |
| PL (1) | PL1756096T3 (de) |
| PT (1) | PT1756096E (de) |
| RU (1) | RU2368612C2 (de) |
| SI (1) | SI1756096T1 (de) |
| TW (1) | TWI287537B (de) |
| WO (1) | WO2005105791A1 (de) |
| ZA (1) | ZA200608886B (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US8399666B2 (en) * | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| ES2581765T3 (es) | 2006-08-24 | 2016-09-07 | University Of Tennessee Research Foundation | Acilanilidas sustituidas y métodos de uso de las mismas |
| JP5275236B2 (ja) | 2006-09-29 | 2013-08-28 | スミスクライン ビーチャム コーポレーション | 置換されたインドール化合物 |
| CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
| US7910583B2 (en) * | 2007-05-04 | 2011-03-22 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists |
| ES2388315T3 (es) | 2007-05-04 | 2012-10-11 | Bristol-Myers Squibb Company | Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G |
| EA016595B1 (ru) * | 2007-07-17 | 2012-06-29 | Бристол-Маерс Сквибб Компани | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения |
| KR100918814B1 (ko) * | 2007-10-04 | 2009-09-25 | 건국대학교 산학협력단 | 인쇄방법을 이용한 세라믹 전자부품 고속제조방법 |
| TW200920369A (en) * | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| WO2009115212A1 (en) * | 2008-03-17 | 2009-09-24 | F. Hoffmann-La Roche Ag | Lxr ligand binding domain (lxr lbd) crystals |
| MX2010012814A (es) * | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| SG184168A1 (en) | 2010-04-08 | 2012-10-30 | Bristol Myers Squibb Co | Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
| US8940716B2 (en) | 2010-05-06 | 2015-01-27 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as GPR119 modulators |
| US8729084B2 (en) | 2010-05-06 | 2014-05-20 | Bristol-Myers Squibb Company | Benzofuranyl analogues as GPR119 modulators |
| RU2598842C2 (ru) * | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
| WO2013173198A1 (en) | 2012-05-16 | 2013-11-21 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| LT2872482T (lt) | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| WO2014139388A1 (en) * | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015061272A1 (en) | 2013-10-22 | 2015-04-30 | Bristol-Myers Squibb Company | Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| EP3402477A4 (de) | 2016-01-11 | 2019-08-21 | The Rockefeller University | Verfahren zur behandlung von erkrankungen im zusammenhang mit aus myeloid abgeleiteten suppressorzellen |
| CN106187899B (zh) * | 2016-06-28 | 2019-07-16 | 绍兴文理学院 | 一种氟代氮杂芳烃的合成方法 |
| JP7072557B2 (ja) | 2016-07-22 | 2022-05-20 | ブリストル-マイヤーズ スクイブ カンパニー | グルコキナーゼ活性化剤およびその使用方法 |
| CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| TWI748194B (zh) * | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
| US20200085810A1 (en) | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
| TWI888447B (zh) | 2019-12-13 | 2025-07-01 | 美商因思博納公司 | 金屬鹽及其用途 |
| CN115028655B (zh) * | 2022-05-20 | 2024-01-16 | 上海大学 | 一种2-三氟甲基-3-碘-吲哚类化合物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR63361B (en) * | 1976-06-24 | 1979-10-22 | Du Pont | Preparation process of antihypertensive hexafluorohydroxyisopropyl bicyclic and tricyclic carbostyrils |
| US4251659A (en) * | 1977-12-22 | 1981-02-17 | E. I. Du Pont De Nemours And Company | Polyfluorohydroxyisopropyl-heterocyclic compounds |
| DK151884C (da) * | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
| JPH0995482A (ja) | 1995-09-29 | 1997-04-08 | Shionogi & Co Ltd | α−置換酢酸を有する複素環誘導体、その製造用中間体ならびにそれを含有する農薬 |
| WO1997019311A1 (en) | 1995-11-17 | 1997-05-29 | Form Rite | Bypass fitting for a transmission fluid cooler |
| DE60211891T2 (de) | 2001-05-15 | 2007-05-24 | F. Hoffmann-La Roche Ag | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes |
| US6472386B1 (en) | 2001-06-29 | 2002-10-29 | Kowa Co., Ltd. | Cyclic diamine compound with 5-membered ring groups |
| GB0216224D0 (en) | 2002-07-12 | 2002-08-21 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-04-26 DE DE602005015962T patent/DE602005015962D1/de not_active Expired - Lifetime
- 2005-04-26 BR BRPI0510599-4A patent/BRPI0510599A/pt not_active IP Right Cessation
- 2005-04-26 MX MXPA06012683A patent/MXPA06012683A/es active IP Right Grant
- 2005-04-26 EP EP05751959A patent/EP1756096B1/de not_active Expired - Lifetime
- 2005-04-26 AT AT05751959T patent/ATE439357T1/de active
- 2005-04-26 DK DK05751959T patent/DK1756096T3/da active
- 2005-04-26 KR KR1020067023014A patent/KR100893449B1/ko not_active Expired - Fee Related
- 2005-04-26 HR HR20090533T patent/HRP20090533T1/xx unknown
- 2005-04-26 SI SI200530765T patent/SI1756096T1/sl unknown
- 2005-04-26 JP JP2007511949A patent/JP4682192B2/ja not_active Expired - Fee Related
- 2005-04-26 CA CA2564563A patent/CA2564563C/en not_active Expired - Fee Related
- 2005-04-26 CN CNA2005800142069A patent/CN1950365A/zh active Pending
- 2005-04-26 PT PT05751959T patent/PT1756096E/pt unknown
- 2005-04-26 ES ES05751959T patent/ES2329489T3/es not_active Expired - Lifetime
- 2005-04-26 NZ NZ550447A patent/NZ550447A/en not_active IP Right Cessation
- 2005-04-26 RU RU2006142746/04A patent/RU2368612C2/ru not_active IP Right Cessation
- 2005-04-26 AU AU2005238176A patent/AU2005238176B2/en not_active Ceased
- 2005-04-26 WO PCT/EP2005/004454 patent/WO2005105791A1/en not_active Ceased
- 2005-04-26 PL PL05751959T patent/PL1756096T3/pl unknown
- 2005-04-27 US US11/115,942 patent/US7173048B2/en not_active Expired - Fee Related
- 2005-04-28 MY MYPI20051897A patent/MY139571A/en unknown
- 2005-04-29 AR ARP050101717A patent/AR049497A1/es unknown
- 2005-04-29 TW TW094113966A patent/TWI287537B/zh not_active IP Right Cessation
-
2006
- 2006-10-19 IL IL178767A patent/IL178767A0/en unknown
- 2006-10-25 ZA ZA200608886A patent/ZA200608886B/en unknown
- 2006-11-29 NO NO20065503A patent/NO20065503L/no not_active Application Discontinuation
- 2006-12-11 US US11/636,925 patent/US7485652B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE439357T1 (de) | Indolylderivate als liver-x-rezeptormodulatoren | |
| CY2017008I2 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| ATE545631T1 (de) | N-(2-benzyl)-2-phenylbutanamide als androgenrezeptormodulatoren | |
| DE602007006531D1 (de) | Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren | |
| ATE510831T1 (de) | Hydrierte benzoäcüthiophenderivate als immunmodulatoren | |
| ATE413874T1 (de) | Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten | |
| ATE537157T1 (de) | Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren | |
| DE602005018190D1 (de) | Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate | |
| ATE523195T1 (de) | Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten | |
| ATE513827T1 (de) | Oxyindol-derivate als 5ht4-rezeptor-agonisten | |
| ATE394391T1 (de) | Indolderivate als histaminrezeptorantagonisten | |
| ATE529429T1 (de) | Tricyclische spiroderivate als crth2-modulatoren | |
| ATE387202T1 (de) | Pyrrolidinderivate als histaminrezeptor-liganden | |
| ATE421511T1 (de) | Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors | |
| DE602004014772D1 (de) | Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors | |
| DE602004014773D1 (de) | Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors | |
| EP1890696A4 (de) | Als orl-1-rezeptormodulatoren geeignete neue 3-spirocyclische indolylderivate | |
| ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
| ATE525354T1 (de) | Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms) | |
| ATE472544T1 (de) | Als via-rezeptor-antagonisten verwendbare indole | |
| DK2447252T3 (da) | Theramuteinmodulatorer | |
| ATE396998T1 (de) | Tetrazyklische imidazobenzodiazepine als gaba- rezeptormodulatoren | |
| DE602006003666D1 (de) | Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten | |
| DE602006015186D1 (de) | Oxindole als kinaseinhibitoren | |
| DE602006008002D1 (de) | Benzofuranylderivate als 5-ht6-rezeptorinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1756096 Country of ref document: EP |